Morphine Sulfate/Naltrexone Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Morphine Sulfate/Naltrexone Hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 24 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Morphine Sulfate/Naltrexone Hydrochloride can convert its Small molecule drug profile and Opioid receptors biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Morphine Sulfate/Naltrexone Hydrochloride (query alias: Morphine Sulfate/Naltrexone Hydrochloride) |
|---|---|
| Modality / target | Small molecule drug; Opioid receptors; Opioid receptors antagonists |
| Highest global status | NDA/BLA |
| Originator | Pfizer Inc. |
| Active developers | Pharmamax Pharmaceuticals Ltd., Chengdu Easton Biopharmaceuticals Co., Ltd. |
The MCP disease footprint includes Cancer Pain. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07666009 | Not Applicable | Not yet recruiting | 100 | Worst pain score during the first 24 hours after surgery |
| NCT07720739 | Not Applicable | Recruiting | 75 | Time to First Rescue Analgesia |
| NCT07678073 | Not Applicable | Recruiting | 68 | Serum ferroptosis-related biomarkers (Fe, TFRC1, GPX4, MDA, ACSL4) and mitochondrial-derived peptides (humanin and MOTS-c) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Multimodal Management for Perioperative Analgesia in Otolaryngology - Head and Neck Free Flap Reconstructive Surgery: A Prospective Study
Phase 4; n=30; evaluation: not stated. Reported fields: Mean Morphine Equivalents During Stay(Mean) = 222.8 Morphine Milligram Equivalents (MME) (Standard Deviation, 121.4); Mean Morphine Equivalents During Stay(Mean) = 101.9 Morphine Milligram Equivalents (MME) (Standard Deviation, 100.0); -
Combined intrathecal fentanyl and morphine for postoperative analgesia after total knee arthroplasty: a randomised controlled trial
Not Applicable; n=111; evaluation: Positive. Reported fields: pain score(at rest and during motion at 6, 12, and 24 h): P-Value = < 0.001; P-Value = < 0.001; P-Value = < 0.001; pain score(at rest and during motion at 6, 12, and 24 h): P-Value = < 0.001; P-Value = < 0.001; P-Value = < 0.001; pain score(at rest and during motion at 6, 12, and 24 h): P-Value = < 0.001; P-Value = < 0.001; P-Value = < 0.001
Mechanisms of Hypoglycemia Associated Autonomic Failure
Phase 2; n=39; evaluation: not stated. Reported fields: -; -; Endogenous Glucose Production (EGP) Response Rate - Morphine Sulfate Study(Mean) = 1.29 mg/kg/min (Standard Deviation, 0.33)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Morphine Sulfate/Naltrexone Hydrochloride addresses Cancer Pain. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2016-10-25 | Daiichi Sankyo, Inc. and Inspirion Delivery Sciences LLC Announce U.S. Licensing Agreement for MorphaBond™ Formulated with SentryBond™ Abuse-Deterrent Technology | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 24 July 2026. Counts and status fields may change as source records update.
